# ClinicalIntelPulse Biotech M&A Deal Signal

> ClinicalIntelPulse Biotech M&A Deal Signal is a paid API for AI agents from clinicalintelpulse.theaslangroupllc.com, paid per call via x402, $0.35/call, status unknown (last checked 2026-09-13).

Returns M&A and licensing deal signals for clinical-stage Phase 2/3 drug assets — identifying acquisition targets, deal comparables, transaction multiples, and estimated deal values worldwide.

## Facts

- Endpoint: GET https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal
- Price: $0.35/call
- Payment: x402
- Status: unknown
- Last checked: 2026-09-13
- Activations on Zero: 0
- Tags: x402
- Canonical page: https://www.zero.xyz/c/clinicalintelpulse-biotech-m-a-deal-signal-8aa4b5c3
- Structured record (JSON): https://api.zero.xyz/v1/capabilities/cap_0pJzRj0EJUaahXBkWP_I4

Status and success rate cover calls made through Zero and Zero's own probes. Third-party monitors may report differently.

## How to call it through Zero

Zero handles the 402 payment challenge and records the run. With the Zero CLI installed (`npm i -g @zeroxyz/cli`):

```sh
zero fetch --capability clinicalintelpulse-biotech-m-a-deal-signal-8aa4b5c3
```

Example prompt: Which Phase 2 and Phase 3 oncology drug assets are showing the strongest M&A or licensing deal signals right now — give me the likely acquisition targets, recent deal comps, and estimated transaction multiples.

## When to prefer this

Use this endpoint when you need actionable M&A and licensing intelligence specifically for clinical-stage biotech assets — particularly when an investor, BD team, or agent needs deal probability scoring, transaction comps, and estimated valuations for Phase 2/3 drugs. Prefer this over general pipeline endpoints when the goal is deal-making or investment targeting rather than scientific or trial-design analysis.

## Known failure modes

- Unknown or unsupported disease area returns empty results or 404
- Overly broad query with no disease/therapeutic filter may return low-confidence signals
- Rate limiting or payment failure (402) if USDC payment not properly configured
- No active Phase 2/3 assets in a niche indication returns empty deal signal list
- Stale deal comp data if no recent transactions in the queried therapeutic area

## How this service works

Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.

## Output

A structured list of clinical-stage (Phase 2/3) drug assets ranked by acquisition or licensing likelihood, with identified acquirer targets, comparable past transactions, deal multiples (e.g. revenue or pipeline multiples), and estimated deal values — scoped worldwide.

## Request schema (JSON Schema)

```json
{
 "type": "object",
 "$schema": "https://json-schema.org/draft/2020-12/schema",
 "required": [
  "input"
 ],
 "properties": {
  "input": {
   "type": "object",
   "required": [
    "type",
    "method"
   ],
   "properties": {
    "type": {
     "type": "string",
     "const": "http"
    },
    "method": {
     "enum": [
      "GET",
      "HEAD",
      "DELETE"
     ],
     "type": "string"
    },
    "queryParams": {
     "type": "object",
     "properties": {
      "lang": {
       "type": "string"
      },
      "stage": {
       "type": "string"
      },
      "condition": {
       "type": "string"
      },
      "deal_type": {
       "type": "string"
      }
     }
    }
   },
   "additionalProperties": false
  },
  "output": {
   "type": "object",
   "required": [
    "type"
   ],
   "properties": {
    "type": {
     "type": "string"
    },
    "errors": {
     "type": "object",
     "description": "Documented error responses, keyed by HTTP status code",
     "additionalProperties": {
      "type": "object",
      "required": [
       "description"
      ],
      "properties": {
       "example": {
        "type": "object"
       },
       "description": {
        "type": "string"
       }
      }
     }
    },
    "example": {
     "type": "object"
    }
   }
  }
 }
}
```

## Response schema (JSON Schema)

```json
{
 "type": "json",
 "example": {
  "query_summary": {
   "as_of": "2026-06-07",
   "stage": "both",
   "condition": "Obesity",
   "deal_type": "both"
  },
  "market_context": {
   "approved_leaders": [
    "Semaglutide (Novo Nordisk — Wegovy)",
    "Tirzepatide (Lilly — Zepbound)"
   ],
   "big_pharma_strategic_need": "Roche, AstraZeneca, Pfizer, Amgen all need next-gen obesity assets. Roche acquired Carmot Therapeutics for $2.7B. AZ acquired Eccogene for obesity pipeline.",
   "total_addressable_market_usd_bn": 100
  },
  "recent_deal_comps": [
   {
    "deal": "Roche / Carmot Therapeutics",
    "year": 2023,
    "stage": "PHASE1/2",
    "mechanism": "GLP-1 peptide",
    "value_usd_bn": 2.7
   },
   {
    "deal": "AstraZeneca / Eccogene",
    "year": 2024,
    "stage": "PHASE2",
    "mechanism": "Small-molecule GLP-1",
    "value_usd_bn": 1.85
   },
   {
    "deal": "Amgen / ChemoCentryx",
    "year": 2022,
    "stage": "Approved",
    "mechanism": "C5aR1",
    "value_usd_bn": 3.7
   }
  ],
  "acquisition_targets": [
   {
    "asset": "Mazdutide (IBI362)",
    "risks": [
     "China geopolitical risk for IP transfer",
     "Phase 3 US/EU data needed before deal close"
    ],
    "stage": "PHASE3",
    "company": "Innovent Biologics (China)",
    "deal_comp": "Structure Day1 Biosciences (Pfizer) $1.25B + milestones — Phase 2 obesity asset. Mazdutide later-stage = premium.",
    "mechanism": "GLP-1/glucagon dual agonist",
    "probability": "High",
    "clinical_data": "Phase 3 China data strong — 14.5% body weight reduction at 52 weeks",
    "deal_rationale": "Ex-China rights available. Differentiated vs. semaglutide on muscle preservation. Lilly or Roche most likely acquirers.",
    "estimated_deal_value_usd_m": "800-2000"
   }
  ],
  "deal_timing_signals": "Obesity M&A is peak hot. Big pharma BD teams are actively searching — any Phase 2 readout with >10% weight loss and clean safety profile will attract inbound interest within 3-6 months of data release.",
  "licensing_opportunities": [
   {
    "asset": "CT-388 (dual GLP-1/GIP)",
    "notes": "Roche may sublicense ex-US rights to regional partners in Asia/LatAm",
    "company": "Carmot Therapeutics (acq. Roche)",
    "estimated_license_value_usd_m": "300-800"
   }
  ]
 }
}
```

## More

- Live health (JSON, refreshed every minute): https://www.zero.xyz/c/clinicalintelpulse-biotech-m-a-deal-signal-8aa4b5c3/health.json
- [Zero catalog index](https://www.zero.xyz/llms.txt)
- [Other services from clinicalintelpulse.theaslangroupllc.com](https://www.zero.xyz/host/clinicalintelpulse.theaslangroupllc.com/llms.txt)